For those of you who have mentioned concerns about big Pharmacare, here is a reference to a brief article, dated January 3, 2019, in the Journal of the American Medical Association (JAMA) - Oncology:
JAMA Oncol. 2019;5(6):893-899
The question to be answered was, "Do the financial incentives within oncology reimbursement affect physicians' practice patterns?"
The main finding: "In this systematic review of 18 studies....most studies found evidence of an association between reimbursement incentives and delivery of cancer care. The ability to self-refer for radiation oncology services was associated with increased use of radiotherapy, and greater profitability of an anticancer drug was associated with increased use of that drug."